Management of CML-blast crisis

• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Saußele, Susanne [VerfasserIn]
• Verfasst von: Voskanyan, Astghik [VerfasserIn]
• Titel: Management of CML-blast crisis
• Verf.angabe: Rüdiger Hehlmann, Susanne Saußele, Astghik Voskanyan, Richard T. Silver
• E-Jahr: 2016
• Jahr: September 2016
• Umfang: 13 S.
• Fussnoten: Gesehen am 06.08.2019 ; Available online 20 October 2016
• Titel Quelle: Enthalten in: Best practice & research
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1999
• Jahr Quelle: 2016
• Band/Heft Quelle: 29(2016), 3, Seite 295-307
• ISSN Quelle: 1532-1924
• DOI: doi:10.1016/j.beha.2016.10.005
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: CML blast crisis
• Sach-SW: Diagnosis
• Sach-SW: Early prediction
• Sach-SW: Prevention
• Sach-SW: Therapy
• K10plus-PPN: 1670666204

Abstract

Tyrosine kinase inhibitors (TKI) have moderately improved survival in BC, but a median survival of less than 1 year is still unsatisfactory. This article reviews the various tests required for diagnosis of BC, features at diagnosis, treatment modalities (intensive chemotherapy, TKI, allo-SCT and a selection of investigational agents), options of prevention and predictors of progression. The best prognosis is observed in patients that achieve a 2nd CP. Allo-SCT probably further improves prognosis of patients in 2nd CP. The choice of TKI should be directed by the mutation profile of the patient. BC can be prevented. A careful analysis of risk factors for progression may help. Current treatment options are combined in a concluding strategy for the management of BC.